Previous Close | 209.21 |
Open | 209.34 |
Bid | 0.00 x 800 |
Ask | 0.00 x 800 |
Day's Range | 206.87 - 209.60 |
52 Week Range | 179.59 - 234.09 |
Volume | |
Avg. Volume | 721,205 |
Market Cap | 17.622B |
Beta (5Y Monthly) | 1.00 |
PE Ratio (TTM) | 48.28 |
EPS (TTM) | 4.34 |
Earnings Date | Apr 23, 2024 - Apr 29, 2024 |
Forward Dividend & Yield | 2.88 (1.37%) |
Ex-Dividend Date | Feb 26, 2024 |
1y Target Est | 246.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for LH
Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today presented the results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The studies demonstrate the value of biomarker testing in closing testing gaps and guiding targeted therapies for patients with epithelial ovarian cancer (EOC).
Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.